Madison Sustainable Equity Fund highlighted stocks like Equifax Inc. (NYSE:EFX) in the Q3 2024 investor letter. Equifax Inc. ...

In a report released today, Andrew Steinerman from J.P. Morgan maintained a Buy rating on Equifax (EFX – Research Report), with a price target ...

Over 40% of participants treated with EFX 50mg for 96 weeks, compared with 0% for placebo, showed regression of liver ...

Equifax (EFX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Enerflex Ltd. (TSE:EFX – Get Free Report)’s share price hit a new 52-week high during mid-day trading on Monday after Acumen Capital raised their price target on the stock from C$12.00 to C$15.00. The ...

JPMorgan analyst Andrew Steinerman lowered the firm’s price target on Equifax (EFX) to $283 from $304 and keeps an Overweight rating on the ...

On Friday, Equifax Inc (EFX) stock saw a decline, ending the day at $248.27 which represents a decrease of $-13.94 or -5.32% from the prior close of $262.21. The stock opened at $257.81 and touched a ...

Enerflex (TSE:EFX – Free Report) had its target price raised by BMO Capital Markets from C$11.00 to C$15.00 in a report ...

The study revealed that after 96 weeks of EFX treatment, over 40% of participants exhibited regression of liver fibrosis, a key indicator of MASH progression. This includes improvements in liver ...

First patients dosed in Phase 3 SYNCHRONY Outcomes study of lead candidate efruxifermin (EFX) in patients with compensated ...